Larvol Delta - Apnimed-Announces-First-Patient-Dosed-in-a-Second-Phase-2-Clinical-Trial-with-AD109-a-Disease-Modifying-Candidate-for-Obstructive-Sleep-Apnea--

aroxybutynin/atomoxetine (AD109) - Apnimed

https://www.businesswire.com/news/home/20210119005241/en/Apnimed-Announces-First-Patient-Dosed-in-a-Second-Phase-2-Clinical-Trial-with-AD109-a-Disease-Modifying-Candidate-for-Obstructive-Sleep-Apnea

Jan 19, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next